What drove the revenue growth for Gujarat Kidney?

The doubling of revenue to **₹82.01 crore** is attributed to the strategic consolidation of Parekhs Hospital following its recent acquisition.

What is the status of the company's IPO funds?

The company is initiating a postal ballot to seek shareholder approval for a variation in the intended objects of its IPO, which involves **₹250 crore** in proceeds.

Did the company appoint a new CEO?

No. The board deferred the planned appointment of a new Chief Executive Officer.

What was the profit after tax for the fiscal year?

The company reported a profit after tax of **₹16.81 crore** for the fiscal year ended March 31, 2026.

Earnings · Hospital & Healthcare · Small cap

Gujarat Kidney revenue hits ₹82 cr after Parekhs Hospital acquisition

Consolidated revenue doubled as the company integrated its new hospital unit. Management is now asking shareholders to approve a change in how it spends IPO proceeds.

— 1 earlier story on Gujarat Kidney And Super Speciality Ltd. →

GKSL By Tipsheet Editorial 29 May 2026 · 2:51 PM IST Verify on BSE · NSE

Mkt cap₹1,084 cr

P/E115.19×

ROE36.29%

Debt / eq.0.15

₹82.01 cr Consolidated revenue for FY26

What's new

Revenue doubled to ₹82.01 cr following the consolidation of Parekhs Hospital.
Profit after tax reached ₹16.81 cr for the fiscal year.
The board is seeking shareholder approval via postal ballot to change the intended objects of its IPO.

Why this matters

The acquisition of Parekhs Hospital has clearly altered the company's financial scale. However, the move to vary the use of IPO proceeds, which involve ₹250 crore in total funds, signals a significant change in capital allocation that requires close scrutiny.

What we're watching

Details on the specific changes to the IPO fund usage.
The timeline for appointing a new CEO after the recent deferral.
Whether the new auditors flag any issues in the upcoming cycles.

The full read

Gujarat Kidney And Super Speciality Ltd reported consolidated revenue of ₹82.01 crore for FY26. This is a doubling of its previous annual figures. The growth follows the integration of Parekhs Hospital, which also helped lift consolidated profit after tax to ₹16.81 crore. While the financials show the impact of inorganic growth, the board's decision to seek shareholder approval for a variation in the objects of its IPO is the more pressing development. The company intends to reallocate ₹250 crore in proceeds. This move suggests a pivot in its capital strategy. Amid these changes, the board deferred the appointment of a new CEO and brought in new internal and secretarial auditors. The company is now in a transition phase. Successful integration of its acquisition must be balanced against a major shift in how it deploys its public capital.

Questions answered

What drove the revenue growth for Gujarat Kidney?: The doubling of revenue to ₹82.01 crore is attributed to the strategic consolidation of Parekhs Hospital following its recent acquisition.
What is the status of the company's IPO funds?: The company is initiating a postal ballot to seek shareholder approval for a variation in the intended objects of its IPO, which involves ₹250 crore in proceeds.
Did the company appoint a new CEO?: No. The board deferred the planned appointment of a new Chief Executive Officer.
What was the profit after tax for the fiscal year?: The company reported a profit after tax of ₹16.81 crore for the fiscal year ended March 31, 2026.

Mentioned: Parekhs Hospital · ₹250 cr IPO proceeds

Primary source BSE · NSE

An independent reading of the company's own disclosure — the primary filing above is the final word.

Story so far

All notes on GKSL →

29 May 2026 · 2:51 PM IST Gujarat Kidney revenue hits ₹82 cr after Parekhs Hospital acquisition
1d ago Gujarat Kidney revenue doubles to ₹82 cr after Parekhs acquisition